Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer
Status: | Recruiting |
---|---|
Conditions: | Colorectal Cancer, Cancer, Cancer |
Therapuetic Areas: | Oncology |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 4/6/2019 |
Start Date: | October 12, 2016 |
A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer
This randomized phase II trial studies how well veliparib or pembrolizumab work with
combination chemotherapy and radiation therapy in treating patients with rectal cancer that
has spread from where it started to nearby tissue or lymph nodes (locally advanced).
Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell
growth. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor
cells to grow and spread. Drugs used in chemotherapy, such as modified (m)FOLFOX6 regimen,
work in different ways to stop the growth of tumor cells, either by killing the cells, by
stopping them from dividing, or by stopping them from spreading. Radiation therapy uses
high-energy x-rays to kill tumor cells and shrink tumors. Giving veliparib or pembrolizumab
with combination chemotherapy and radiation therapy may kill more tumor cells, make the tumor
smaller, and reduce the amount of normal tissue that needs to be removed.
combination chemotherapy and radiation therapy in treating patients with rectal cancer that
has spread from where it started to nearby tissue or lymph nodes (locally advanced).
Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell
growth. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor
cells to grow and spread. Drugs used in chemotherapy, such as modified (m)FOLFOX6 regimen,
work in different ways to stop the growth of tumor cells, either by killing the cells, by
stopping them from dividing, or by stopping them from spreading. Radiation therapy uses
high-energy x-rays to kill tumor cells and shrink tumors. Giving veliparib or pembrolizumab
with combination chemotherapy and radiation therapy may kill more tumor cells, make the tumor
smaller, and reduce the amount of normal tissue that needs to be removed.
PRIMARY OBJECTIVES:
I. To demonstrate an absolute improvement in neoadjuvant rectal cancer (NAR) score for the
experimental regimen as compared to concurrently randomized control patients.
SECONDARY OBJECTIVES:
I. To compare overall survival (OS). II. To compare disease-free survival (DFS). III. To
compare the rate of pathologic complete response (pCR) (nodes and tumor).
IV. To compare the rate of sphincter preservation.
EXPLORATORY OBJECTIVES:
I. To estimate the rate of disease progression during chemotherapy (prior to chemoradiation).
II. To compare the rate of clinical complete response rate (cCR). III. To compare the rate of
negative circumferential margin. IV. To compare the rate of completion of all cycles of
neoadjuvant chemotherapy.
V. To compare the rate of completion of full course of chemoradiation. VI. To compare the
toxicity and safety between interventions. VII. To explore the correlative molecular
predictors of response and distant failure.
VIII. To explore the relationship between radiographic findings and pathologic outcomes.
OUTLINE: Patients are randomized to 1 of 3 treatment arms.
ARM I: Patients receive mFOLFOX6 regimen consisting of oxaliplatin intravenously (IV) over 2
hours, leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV continuously over
46-48 hours on days 1-2. Treatment repeats every 2 weeks for 8 courses in the absence of
disease progression or unacceptable toxicity. 3-4 weeks after last does of mFOLFOX6 patient
undergo radiation therapy (RT) and receive capecitabine orally (PO) twice daily (BID)
Monday-Friday for 5 weeks in the absence of disease progression or unacceptable toxicity.
ARM II: Patients receive mFOLFOX6 regimen consisting of oxaliplatin IV over 2 hours,
leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV continuously over 46-48
hours on days 1-2. Treatment repeats every 2 weeks for 8 courses in the absence of disease
progression or unacceptable toxicity. 3-4 weeks after last does of mFOLFOX6 patient undergo
RT and receive capecitabine PO BID and veliparib PO BID Monday-Friday for 5 weeks in the
absence of disease progression or unacceptable toxicity.
ARM III: Patients receive mFOLFOX6 regimen consisting of oxaliplatin IV over 2 hours,
leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV continuously over 46-48
hours on days 1-2. Treatment repeats every 2 weeks for 8 courses in the absence of disease
progression or unacceptable toxicity. 3-4 weeks after last does of mFOLFOX6 patient undergo
RT and receive capecitabine PO BID Monday-Friday for 5 weeks. They also receive pembrolizumab
IV over 30 minutes every 3 weeks beginning on day 1 of RT for up to 6 courses in the absence
of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at 30 days and every 6 months
for up to 3 years.
I. To demonstrate an absolute improvement in neoadjuvant rectal cancer (NAR) score for the
experimental regimen as compared to concurrently randomized control patients.
SECONDARY OBJECTIVES:
I. To compare overall survival (OS). II. To compare disease-free survival (DFS). III. To
compare the rate of pathologic complete response (pCR) (nodes and tumor).
IV. To compare the rate of sphincter preservation.
EXPLORATORY OBJECTIVES:
I. To estimate the rate of disease progression during chemotherapy (prior to chemoradiation).
II. To compare the rate of clinical complete response rate (cCR). III. To compare the rate of
negative circumferential margin. IV. To compare the rate of completion of all cycles of
neoadjuvant chemotherapy.
V. To compare the rate of completion of full course of chemoradiation. VI. To compare the
toxicity and safety between interventions. VII. To explore the correlative molecular
predictors of response and distant failure.
VIII. To explore the relationship between radiographic findings and pathologic outcomes.
OUTLINE: Patients are randomized to 1 of 3 treatment arms.
ARM I: Patients receive mFOLFOX6 regimen consisting of oxaliplatin intravenously (IV) over 2
hours, leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV continuously over
46-48 hours on days 1-2. Treatment repeats every 2 weeks for 8 courses in the absence of
disease progression or unacceptable toxicity. 3-4 weeks after last does of mFOLFOX6 patient
undergo radiation therapy (RT) and receive capecitabine orally (PO) twice daily (BID)
Monday-Friday for 5 weeks in the absence of disease progression or unacceptable toxicity.
ARM II: Patients receive mFOLFOX6 regimen consisting of oxaliplatin IV over 2 hours,
leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV continuously over 46-48
hours on days 1-2. Treatment repeats every 2 weeks for 8 courses in the absence of disease
progression or unacceptable toxicity. 3-4 weeks after last does of mFOLFOX6 patient undergo
RT and receive capecitabine PO BID and veliparib PO BID Monday-Friday for 5 weeks in the
absence of disease progression or unacceptable toxicity.
ARM III: Patients receive mFOLFOX6 regimen consisting of oxaliplatin IV over 2 hours,
leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV continuously over 46-48
hours on days 1-2. Treatment repeats every 2 weeks for 8 courses in the absence of disease
progression or unacceptable toxicity. 3-4 weeks after last does of mFOLFOX6 patient undergo
RT and receive capecitabine PO BID Monday-Friday for 5 weeks. They also receive pembrolizumab
IV over 30 minutes every 3 weeks beginning on day 1 of RT for up to 6 courses in the absence
of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at 30 days and every 6 months
for up to 3 years.
Inclusion Criteria:
- The patient must have signed and dated an Institutional Review Board (IRB)-approved
consent form that conforms to federal and institutional guidelines
- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
- Diagnosis of adenocarcinoma of the rectum with the major portion of the tumor intact;
Note: prior to randomization, the investigator must specify and document each of the
following:
- Distance of the lowest tumor margin from the anal verge; and
- Intent for sphincter sparing or non-sphincter sparing surgical resection
according to the primary surgeon; and
- The majority of the untreated tumor must be < 12 cm from the anal verge or below
the peritoneal reflection as determined by the treating surgeon
- The tumor must be clinically determined to be locally advanced stage II or stage III
rectal cancer, and must also meet any ONE of the following criteria:
- Distal location (as defined by measurement on magnetic resonance imaging [MRI],
transrectal ultrasound [ERUS]/pelvic computed tomography [CT] [with IV contrast]
scan or palpable on digital rectal examination [DRE]): cT3-4 =< 5 cm from the
anal verge, any N
- Bulky: any cT4 or evidence that the tumor is adjacent to (defined as within 3 mm
of) the mesorectal fascia on MRI or ERUS/pelvic CT (with IV contrast) scan
- High risk for metastatic disease with 4 or more regional lymph nodes (cN2);
clinical nodal or "cN" status for eligibility includes the total number of nodes
(N2 = 4 or more) in the mesorectal and superior rectal stations measuring >= 1.0
cm in any axis on cross sectional or endoscopic imaging; Note: nodes must measure
1.0 cm or greater to be considered positive for this eligibility requirement
- Not a candidate for sphincter-sparing surgical resection prior to neoadjuvant
therapy (as planned by the primary surgeon)
- Note: clinical stage of the primary tumor and nodes may be determined
locally by rectal endoscopic ultrasound or pelvic MRI (MRI is strongly
preferred); CT scan with IV contrast is acceptable provided there is
evidence of T4 and/or N2 disease
- Patients must have the ability to swallow and retain oral medication
- Absolute neutrophil count (ANC) must be >= 1200/mm^3 within 28 days before
randomization
- Platelet count must be >= 100,000/mm^3 within 28 days before randomization
- Hemoglobin must be >= 10 g/dL within 28 days before randomization
- Total bilirubin must be =< ULN (upper limit of normal) for the lab unless the patient
has a bilirubin elevation > ULN to 1.5 x ULN due to Gilbert's disease or similar
syndrome involving slow conjugation of bilirubin within 28 days before randomization
- Alkaline phosphatase must be =< 3 x ULN for the lab within 28 days before
randomization
- Aspartate aminotransferase (AST) must be =< 3 x ULN for the lab within 28 days before
randomization;
- Note: if alanine aminotransferase (ALT) is performed instead of AST (per
institution's standard practice), the ALT value must be =< 3 x ULN; if both were
performed, the AST must also be =< 3 x ULN; if AST and/or ALT is >= ULN but =< 3
x ULN, serologic testing for hepatitis B and C must be performed and results for
viral infection must be negative
- Serum creatinine =< ULN for the lab and measured or calculated creatinine clearance >
60 mL/min within 28 days before randomization
- Serum potassium, magnesium, and calcium levels within 28 days before randomization
must be within normal limits (WNL) for the lab within 28 days before randomization
- International normalized ratio of prothrombin time (INR) within 28 days before
randomization must be =< ULN for the lab; patients who are therapeutically treated
with an agent such as warfarin may participate if they are on a stable dose and no
underlying abnormality in coagulation parameters exists per medical history
- Patients with acquired immunodeficiency syndrome (AIDS-related illnesses) or known
human immunodeficiency virus (HIV) disease must:
- Have a cluster of differentiation (CD)4 count >= 200 cells/uL within 30 days
before beginning study therapy
- Be off all antiretroviral therapy (prophylaxis/treatment) more than 60 days
before beginning study therapy, and
- Have no evidence of opportunistic infections
- Pregnancy test (urine or serum beta-human chorionic gonadotropin [HCG]) done within 72
hours before randomization must be negative (for women of childbearing potential
only); if urine pregnancy results are positive or cannot be confirmed as negative, a
serum pregnancy test will be required
Exclusion Criteria:
- Rectal cancer histology other than adenocarcinoma (i.e., sarcoma, lymphoma, squamous
cell carcinoma, mucosal melanoma, etc.)
- Definitive clinical or radiologic evidence of metastatic disease; required imaging
studies must have been performed within 28 days prior to randomization; Note: Distant
clinical staging to exclude patients with overt metastatic disease is determined by:
- Chest: CT scan (preferred); chest x-ray posterioranterior (PA) and lateral
(acceptable); or positron emission tomography (PET) scan (acceptable)
- Abdomen: CT scan with IV contrast (preferred); or MRI (acceptable)
- Pelvis: MRI (preferred) or CT scan with IV contrast (acceptable)
- (It is recommended that the same imaging tests that are performed before
randomization be used at follow-up time points; Note: CT scans of the
abdomen and pelvis must be performed with IV contrast)
- History of prior invasive rectal malignancy, regardless of disease-free interval
- Cardiac disease that would preclude the use of any of the drugs included in the GI002
treatment regimen; this includes but is not limited to:
- Clinically unstable cardiac disease, including unstable atrial fibrillation,
symptomatic bradycardia, unstable congestive heart failure, active myocardial
ischemia, or indwelling temporary pacemaker
- Ventricular tachycardia or supraventricular tachycardia that requires treatment
with class Ia antiarrhythmic drugs (e.g., quinidine, procainamide, disopyramide)
or class III antiarrhythmic drug (e.g., sotalol, amiodarone, dofetilide); use of
other antiarrhythmic drugs is permitted
- Second- or third-degree atrioventricular (AV) block unless treated with a
permanent pacemaker
- Complete left bundle branch block (LBBB)
- History of long QT syndrome
- Corrected QT (QTc) >= 450ms
- Sensory or motor neuropathy >= grade 2
- History of, or any evidence of active, non-infectious pneumonitis
- Active inflammatory bowel disease (i.e., patients requiring current medical
interventions or who are symptomatic) or have a history of abdominal surgery or other
medical condition that may, in the opinion of the treating physician, interfere with
gastrointestinal motility or absorption
- Active autoimmune disease that has required systemic treatment within the past 2 years
(i.e., with use of modifying agents, corticosteroids, or immunosuppressive drugs);
replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid
replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a
form of systemic treatment
- History of active TB (Bacillus tuberculosis)
- Active or chronic infection requiring systemic therapy
- Diagnosis of immunodeficiency or receiving systemic steroid therapy or any other form
of immunosuppressive therapy within 7 days prior to the first dose of study therapy;
the use of physiologic doses of corticosteroids may be approved after consultation
with the study principal investigator (PI)
- Active seizure disorder uncontrolled by medication
- Any antineoplastic therapy for this cancer before randomization
- Synchronous colon cancer
- Other invasive cancer within 5 years before randomization; exceptions are colonic
polyps, non-melanoma skin cancer or carcinoma-in-situ of the cervix
- Antineoplastic therapy (e.g. chemotherapy or targeted therapy) for other invasive
cancer within 5 years before randomization; (for the purposes of this study, hormonal
therapy is not considered chemotherapy)
- Prior treatment with an investigational compound being tested in this study (e.g.,
poly ADP ribose polymerase [PARP] inhibitor, anti-PD-1, anti-PD-L1, or anti-PD-L2)
- Receipt of live vaccination within 28 days before randomization; seasonal flu vaccines
that do not contain live virus are permitted
- Major surgery within 4 weeks before randomization
- Any therapeutic pelvic radiation
- Known homozygous DPD (dihydro pyrimidine dehydrogenase) deficiency
- Pregnant women
- Nursing women who are unwilling to discontinue nursing
- Men or women of childbearing potential who are unwilling to employ adequate
contraception (e.g., hormonal or barrier method of birth control; abstinence) for the
duration of study treatment and for 4 months after the last dose of study therapy
- Co-morbid illnesses or other concurrent disease that, in the judgement of the
clinician obtaining informed consent, would make the patient inappropriate for entry
into this study or interfere significantly with the proper assessment of safety and
toxicity of the prescribed regimens or prevent required follow-up
We found this trial at
632
sites
7500 Mercy Road
Omaha, Nebraska 68124
Omaha, Nebraska 68124
Principal Investigator: Ralph J. Hauke
Phone: 402-393-3110
Click here to add this to my saved trials
1201 Camino de Salud Northeast
Albuquerque, New Mexico 87131
Albuquerque, New Mexico 87131
(505) 272-4946
Principal Investigator: Bridget N. Fahy
Phone: 505-925-0366
University of New Mexico Cancer Center It’s been 40 years since the New Mexico State...
Click here to add this to my saved trials
2545 Schoenersville Rd
Bethlehem, Pennsylvania 18017
Bethlehem, Pennsylvania 18017
(484) 884-2200
Principal Investigator: Samir Narayan
Phone: 734-712-3671
Lehigh Valley Hospital - Muhlenberg At Lehigh Valley Health Network, we continually go the extra...
Click here to add this to my saved trials
75 Francis street
Boston, Massachusetts 02115
Boston, Massachusetts 02115
(617) 732-5500
Principal Investigator: Osama E. Rahma
Phone: 412-339-5294
Brigham and Women's Hosp Boston’s Brigham and Women’s Hospital (BWH) is an international leader in...
Click here to add this to my saved trials
330 Brookline Ave
Boston, Massachusetts 02215
Boston, Massachusetts 02215
617-667-7000
Principal Investigator: Osama E. Rahma
Phone: 617-667-9925
Beth Israel Deaconess Medical Center Beth Israel Deaconess Medical Center (BIDMC) is one of the...
Click here to add this to my saved trials
Bremerton, Washington 98310
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Click here to add this to my saved trials
1 South Prospect Street
Burlington, Vermont 05401
Burlington, Vermont 05401
802-656-8990
Principal Investigator: Christopher J. Anker
Click here to add this to my saved trials
3500 Gaston Avenue
Dallas, Texas 75246
Dallas, Texas 75246
1.800.422.9567
Principal Investigator: Katerina O. Wells
Phone: 800-422-9567
Baylor University Medical Center Baylor University Medical Center in Dallas, TX is ranked nationally in...
Click here to add this to my saved trials
1500 E Duarte Rd
Duarte, California 91010
Duarte, California 91010
(626) 256-4673
Principal Investigator: Marwan G. Fakih
Phone: 800-826-4673
City of Hope Comprehensive Cancer Center City of Hope is a leading research and treatment...
Click here to add this to my saved trials
1 Hurley Plaza
Flint, Michigan 48503
Flint, Michigan 48503
(810) 262-9000
Principal Investigator: Samir Narayan
Phone: 734-712-3671
Hurley Medical Center From its founding in 1908, Hurley Medical Center has devoted itself to...
Click here to add this to my saved trials
301 University Blvd
Galveston, Texas 77555
Galveston, Texas 77555
(409) 772-1011
Principal Investigator: Solly S. Chedid
Phone: 409-772-1950
University of Texas Medical Branch Established in 1891 as the University of Texas Medical Department,...
Click here to add this to my saved trials
100 Michigan Street Northeast
Grand Rapids, Michigan 49503
Grand Rapids, Michigan 49503
616.391.9000
Principal Investigator: Kathleen J. Yost
Phone: 412-339-5294
Helen DeVos Children's Hospital at Spectrum Health Helen DeVos Children's Hospital, located in Grand Rapids,...
Click here to add this to my saved trials
524 South Park Street
Kalamazoo, Michigan 49007
Kalamazoo, Michigan 49007
(269) 341-7654
Principal Investigator: Kathleen J. Yost
Phone: 616-391-1230
Bronson Methodist Hospital Our healthcare system serves patients and families throughout southwest Michigan and northern...
Click here to add this to my saved trials
200 North Park Street
Kalamazoo, Michigan 49007
Kalamazoo, Michigan 49007
(269) 382-2500
Principal Investigator: Kathleen J. Yost
Phone: 616-391-1230
West Michigan Cancer Center In 1994, Borgess Health Alliance and Bronson Healthcare Group opened the...
Click here to add this to my saved trials
529 West Markham Street
Little Rock, Arkansas 72205
Little Rock, Arkansas 72205
(501) 686-7000
Principal Investigator: Liudmila N. Schafer
Phone: 501-686-8274
University of Arkansas for Medical Sciences The University of Arkansas for Medical Sciences (UAMS) in...
Click here to add this to my saved trials
8700 Beverly Blvd # 8211
Los Angeles, California 90048
Los Angeles, California 90048
(1-800-233-2771)
Principal Investigator: Richard Tuli
Phone: 310-423-8965
Cedars Sinai Med Ctr Cedars-Sinai is known for providing the highest quality patient care. Our...
Click here to add this to my saved trials
300 Community Drive
Manhasset, New York 11030
Manhasset, New York 11030
(516) 562-0100
Principal Investigator: Anna T. Levy
Phone: 516-734-8896
North Shore University Hospital North Shore-LIJ Health System includes 16 award-winning hospitals and nearly 400...
Click here to add this to my saved trials
401 College Street
Richmond, Virginia 23298
Richmond, Virginia 23298
(804) 828-0450
Principal Investigator: Emma C. Fields
Phone: 412-339-5294
Virginia Commonwealth University Massey Cancer Center Founded in 1974, VCU Massey Cancer Center is a...
Click here to add this to my saved trials
60 Crittenden Blvd # 70
Rochester, New York 14642
Rochester, New York 14642
(585) 275-2121
Principal Investigator: Yuhchyau Chen
Phone: 585-275-5830
University of Rochester The University of Rochester is one of the country's top-tier research universities....
Click here to add this to my saved trials
1100 Fairview Avenue North
Seattle, Washington 98109
Seattle, Washington 98109
(206) 667-5000
Principal Investigator: Stacey A. Cohen
Phone: 800-804-8824
Fred Hutchinson Cancer Research Center At Fred Hutchinson Cancer Research Center, our interdisciplinary teams of...
Click here to add this to my saved trials
825 Eastlake Ave E
Seattle, Washington 98109
Seattle, Washington 98109
(206) 288-7222
Principal Investigator: Stacey A. Cohen
Phone: 800-804-8824
Seattle Cancer Care Alliance Seattle Cancer Care Alliance (SCCA) is a cancer treatment center that...
Click here to add this to my saved trials
3900 W Avera Drive
Sioux Falls, South Dakota 57108
Sioux Falls, South Dakota 57108
(605) 322-4700
Principal Investigator: Benjamin M. Solomon
Phone: 888-634-7268
Avera Cancer Institute Avera, the health ministry of the Benedictine and Presentation Sisters, is a...
Click here to add this to my saved trials
808 North 39th Avenue
Yakima, Washington 98902
Yakima, Washington 98902
Principal Investigator: John A. Keech
Phone: 509-574-3535
Click here to add this to my saved trials
98-1079 Moanalua Road
'Aiea, Hawaii 96701
'Aiea, Hawaii 96701
Principal Investigator: Kenneth N. Sumida
Phone: 808-486-6000
Click here to add this to my saved trials
'Aiea, Hawaii 96701
Principal Investigator: Kenneth N. Sumida
Phone: 808-487-7447
Click here to add this to my saved trials
2226 Liliha Street
'Aiea, Hawaii 96701
'Aiea, Hawaii 96701
Principal Investigator: Kenneth N. Sumida
Phone: 808-678-9000
Click here to add this to my saved trials
Aberdeen, South Dakota 57401
Principal Investigator: Benjamin M. Solomon
Phone: 605-622-8700
Click here to add this to my saved trials
1200 Old York Road
Abington, Pennsylvania 19001
Abington, Pennsylvania 19001
(215) 481–2000
Principal Investigator: Willard G. Andrews
Phone: 215-481-2402
Abington Memorial Hospital Abington Memorial Hospital (AMH) is a 665-bed, regional referral center and teaching...
Click here to add this to my saved trials
Adrian, Michigan 49221
Principal Investigator: Rex B. Mowat
Phone: 517-265-0116
Click here to add this to my saved trials
1 Akron General Avenue
Akron, Ohio 44307
Akron, Ohio 44307
Principal Investigator: Esther H. Rehmus
Phone: 866-223-8100
Click here to add this to my saved trials
Albemarle, North Carolina 28002
Principal Investigator: Kunal C. Kadakia
Phone: 800-804-9376
Click here to add this to my saved trials
Albuquerque, New Mexico 87109
Principal Investigator: Bridget N. Fahy
Phone: 505-272-0530
Click here to add this to my saved trials
Allentown, Pennsylvania 18103
Principal Investigator: Samir Narayan
Phone: 734-712-3671
Click here to add this to my saved trials
Ames, Iowa 50010
Principal Investigator: Debra M. Prow
Phone: 515-956-4132
Click here to add this to my saved trials
Ames, Iowa 50010
Principal Investigator: Debra M. Prow
Phone: 515-956-4132
Click here to add this to my saved trials
2000 E Greenville St
Anderson, South Carolina 29621
Anderson, South Carolina 29621
(864) 512-4640
Principal Investigator: Leander I. Cannick
Phone: 864-512-4651
AnMedical Health Cancer Center Cancer is the general term for a group of more than...
Click here to add this to my saved trials
1500 East Medical Center Drive
Ann Arbor, Michigan 48109
Ann Arbor, Michigan 48109
800-865-1125
Principal Investigator: Kyle C. Cuneo
University of Michigan Comprehensive Cancer Center The U-M Comprehensive Cancer Center's mission is the conquest...
Click here to add this to my saved trials
5301 McAuley Drive
Ann Arbor, Michigan 48197
Ann Arbor, Michigan 48197
734-712-3456
Principal Investigator: Samir Narayan
Phone: 734-712-3671
Saint Joseph Mercy Hospital St. Joseph Mercy Ann Arbor Hospital is a 537-bed teaching hospital...
Click here to add this to my saved trials
Antioch, California 94531
Principal Investigator: Tatjana Kolevska
Phone: 877-642-4691
Click here to add this to my saved trials
Arlington Heights, Illinois 60005
Principal Investigator: Stephen S. Nigh
Phone: 847-618-4968
Click here to add this to my saved trials
921 North Oak Park Boulevard
Arroyo Grande, California 93420
Arroyo Grande, California 93420
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
Click here to add this to my saved trials
Asheville, North Carolina 28801
Principal Investigator: Christopher H. Chay
Phone: 828-213-4150
Click here to add this to my saved trials
1625 Maple Lane
Ashland, Wisconsin 54806
Ashland, Wisconsin 54806
Principal Investigator: Bret E. Friday
Phone: 218-786-3308
Click here to add this to my saved trials
Ashland, Wisconsin 54806
Principal Investigator: Bret E. Friday
Phone: 218-786-3308
Click here to add this to my saved trials
Atlanta, Georgia 30322
Principal Investigator: Christina S. Wu
Phone: 404-778-1868
Click here to add this to my saved trials
550 Peachtree St NE
Atlanta, Georgia 30308
Atlanta, Georgia 30308
(404) 686-4411
Principal Investigator: Christina S. Wu
Phone: 888-946-7447
Emory University Hospital Midtown Emory University Hospital Midtown is a 511-bed community-based, acute care teaching...
Click here to add this to my saved trials
Atlanta, Georgia 30342
Principal Investigator: Christina S. Wu
Phone: 412-339-5294
Click here to add this to my saved trials
Auburn, California 95603
Principal Investigator: Ari D. Baron
Phone: 415-209-2686
Click here to add this to my saved trials
Auburn, Washington 98001
Principal Investigator: John A. Keech
Phone: 253-887-9333
Click here to add this to my saved trials
Aurora, Colorado 80012
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Click here to add this to my saved trials
12605 East 16th Avenue
Aurora, Colorado 80045
Aurora, Colorado 80045
720-848-0000
Principal Investigator: Karyn A. Goodman
Phone: 720-848-0650
University of Colorado Hospital, Site Top medical professionals, superior medicine and progressive change make University...
Click here to add this to my saved trials
2000 Ogden Ave
Aurora, Illinois 60504
Aurora, Illinois 60504
(630) 978-6200
Principal Investigator: Kendrith M. Rowland
Phone: 630-978-6212
Rush - Copley Medical Center Rush-Copley is proud to be the leading provider of health...
Click here to add this to my saved trials
Bakersfield, California 93301
Principal Investigator: Arta M. Monjazeb
Phone: 661-323-4673
Click here to add this to my saved trials
Ballwin, Missouri 63011
Principal Investigator: Jay W. Carlson
Phone: 314-251-7058
Click here to add this to my saved trials
6701 N Charles St
Baltimore, Maryland 21204
Baltimore, Maryland 21204
(443) 849-2000
Principal Investigator: Mei Tang
Phone: 443-849-3706
Greater Baltimore Medical Center The 255-bed medical center (acute and sub-acute care) is located on...
Click here to add this to my saved trials
489 State St
Bangor, Maine 04401
Bangor, Maine 04401
(207) 973-7000
Principal Investigator: Thomas H. Openshaw
Phone: 207-973-4274
Eastern Maine Medical Center Located in Bangor, Eastern Maine Medical Center (EMMC) serves communities throughout...
Click here to add this to my saved trials
Baton Rouge, Louisiana 70809
Principal Investigator: David S. Hanson
Phone: 225-215-1353
Click here to add this to my saved trials
Baton Rouge, Louisiana 70809
Principal Investigator: David S. Hanson
Phone: 225-215-1353
Click here to add this to my saved trials
Baton Rouge, Louisiana 70805
Principal Investigator: David S. Hanson
Phone: 225-215-1353
Click here to add this to my saved trials
4950 Essen Lane
Baton Rouge, Louisiana 70809
Baton Rouge, Louisiana 70809
Principal Investigator: David S. Hanson
Phone: 225-757-0343
Click here to add this to my saved trials
265 Fremont St
Battle Creek, Michigan 49017
Battle Creek, Michigan 49017
(269) 245-8166
Principal Investigator: Kathleen J. Yost
Phone: 616-391-1230
Bronson Battle Creek As a proud member of the Battle Creek community, we believe everyone...
Click here to add this to my saved trials
Bay City, Michigan 48706
Principal Investigator: Kiran Devisetty
Phone: 313-576-9790
Click here to add this to my saved trials
Bayamon, 00959
Principal Investigator: Luis Baez-Diaz
Phone: 787-395-7085
Click here to add this to my saved trials
Beachwood, Ohio 44122
Principal Investigator: Jennifer A. Dorth
Phone: 800-641-2422
Click here to add this to my saved trials
3535 Pentagon Boulevard
Beavercreek, Ohio 45431
Beavercreek, Ohio 45431
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
Click here to add this to my saved trials
Bellevue, Washington 98004
Principal Investigator: John A. Keech
Phone: 425-688-5407
Click here to add this to my saved trials
Bemidji, Minnesota 56601
Principal Investigator: Preston D. Steen
Phone: 218-333-5000
Click here to add this to my saved trials
Berkeley, California 94704
Principal Investigator: Ari D. Baron
Phone: 415-209-2686
Click here to add this to my saved trials
Berlin, Vermont 05602
Principal Investigator: Christopher J. Anker
Phone: 802-225-5400
Click here to add this to my saved trials
Billings, Montana 59101
Principal Investigator: Benjamin T. Marchello
Phone: 800-996-2663
Click here to add this to my saved trials
1233 North 30th Street
Billings, Montana 59101
Billings, Montana 59101
406-237-7000
Principal Investigator: Keren Sturtz
Phone: 406-969-6060
Saint Vincent Healthcare The Sisters of Charity of Leavenworth, Kansas, founded St. Vincent Healthcare in...
Click here to add this to my saved trials
Birmingham, Alabama 35233
Principal Investigator: Andrew M. McDonald
Phone: 205-934-0220
Click here to add this to my saved trials
300 N. Seventh St.
Bismarck, North Dakota 58501
Bismarck, North Dakota 58501
(701) 323-6000
Principal Investigator: Preston D. Steen
Phone: 701-323-5760
Sanford Bismarck Medical Center Whether your stay in our hospital is one day for same...
Click here to add this to my saved trials
Boise, Idaho 83706
Principal Investigator: Benjamin T. Marchello
Phone: 734-712-3671
Click here to add this to my saved trials
Bolivar, Missouri 65613
Principal Investigator: Rakesh Gaur
Phone: 800-328-6010
Click here to add this to my saved trials
Bonne Terre, Missouri 63628
Principal Investigator: Bryan A. Faller
Phone: 314-996-5569
Click here to add this to my saved trials
55 Fruit St
Boston, Massachusetts 02114
Boston, Massachusetts 02114
(617) 724-4000
Principal Investigator: Osama E. Rahma
Phone: 877-726-5130
Massachusetts General Hospital Cancer Center An integral part of one of the world
Click here to add this to my saved trials
450 Brookline Ave
Boston, Massachusetts 2215
Boston, Massachusetts 2215
617-632-3000
Principal Investigator: Osama E. Rahma
Phone: 877-442-3324
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
Click here to add this to my saved trials
1100 Balsam Ave
Boulder, Colorado 80304
Boulder, Colorado 80304
(303) 440-2273
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Boulder Community Hospital Founded in 1922 as a community-owned and operated not-for-profit hospital, Boulder Community...
Click here to add this to my saved trials
Boulder, Colorado 80303
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Click here to add this to my saved trials
915 Highland Blvd
Bozeman, Montana 59715
Bozeman, Montana 59715
(406) 414-5000
Principal Investigator: Benjamin T. Marchello
Phone: 406-969-6060
Bozeman Deaconess Hospital Bozeman Deaconess Hospital is a Joint Commission certified, licensed Level III trauma...
Click here to add this to my saved trials
Brainerd, Minnesota 56401
Principal Investigator: Bret E. Friday
Phone: 412-339-5294
Click here to add this to my saved trials
Bremerton, Washington 98310
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Click here to add this to my saved trials
Brewer, Maine 04412
Principal Investigator: Thomas H. Openshaw
Phone: 800-987-3005
Click here to add this to my saved trials
Bridgeport, West Virginia 26330
Principal Investigator: Malcolm D. Mattes
Phone: 304-293-7374
Click here to add this to my saved trials
Bronx, New York 10467
Principal Investigator: Rafi Kabarriti
Phone: 718-379-6866
Click here to add this to my saved trials
Bronx, New York 10461
Principal Investigator: Rafi Kabarriti
Phone: 718-379-6866
Click here to add this to my saved trials
Bronx, New York 10461
Principal Investigator: Rafi Kabarriti
Phone: 718-379-6866
Click here to add this to my saved trials
30 Lawrence Road
Broomall, Pennsylvania 19008
Broomall, Pennsylvania 19008
Principal Investigator: Rachelle M. Lanciano
Phone: 610-284-8237
Click here to add this to my saved trials
Brownstown, Michigan 48183
Principal Investigator: Eleanor M. Walker
Phone: 313-916-3721
Click here to add this to my saved trials
Bryan, Texas 77802
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Click here to add this to my saved trials
Burien, Washington 98166
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Click here to add this to my saved trials
1501 Trousdale Drive
Burlingame, California 94010
Burlingame, California 94010
Principal Investigator: Ari D. Baron
Phone: 650-696-4487
Click here to add this to my saved trials
Burlington, Vermont 05405
Principal Investigator: Christopher J. Anker
Phone: 802-656-4101
Click here to add this to my saved trials
Burlington, Wisconsin 53105
Principal Investigator: Federico Augusto H. Sanchez
Phone: 414-302-2304
Click here to add this to my saved trials
201 E Nicollet Blvd
Burnsville, Minnesota 55337
Burnsville, Minnesota 55337
(952) 892-2000
Principal Investigator: Paul W. Sperduto
Phone: 952-993-1517
Fairview Ridges Hospital Fairview Ridges Hospital is a 150-bed, Level III Trauma Care facility, offering...
Click here to add this to my saved trials
400 South Clark Street
Butte, Montana 59701
Butte, Montana 59701
406-723-2500
Principal Investigator: Keren Sturtz
Phone: 406-723-2621
Saint James Community Hospital and Cancer Treatment Center St. James Healthcare has played an important...
Click here to add this to my saved trials
3123 Medical Dr
Caldwell, Idaho 83605
Caldwell, Idaho 83605
Principal Investigator: Benjamin T. Marchello
Phone: 734-712-3671
Click here to add this to my saved trials
Cameron Park, California 95682
Principal Investigator: Ari D. Baron
Phone: 415-209-2686
Click here to add this to my saved trials
Click here to add this to my saved trials
211 Saint Francis Drive
Cape Girardeau, Missouri 63703
Cape Girardeau, Missouri 63703
573-331-3000
Principal Investigator: Bryan A. Faller
Phone: 573-334-2230
Saint Francis Medical Center Saint Francis Medical Center is a 282-bed facility serving more than...
Click here to add this to my saved trials